Nasopharyngeal carcinoma, susceptibility to, 1
MONDO:0011775Any nasopharyngeal carcinoma in which the cause of the disease is a mutation in the TP53 gene.
Also known as: TP53 nasopharyngeal carcinoma, nasopharyngeal carcinoma 1, nasopharyngeal carcinoma caused by mutation in TP53, nasopharyngeal carcinoma, somatic, nasopharyngeal carcinoma, susceptibility to, 1, NPC, Npca, nasopharyngeal cancer
53 clinical trials for this condition and its sub-types, 21 tagged with Nasopharyngeal carcinoma, susceptibility to, 1 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
Disease control Not yet recruitingThis trial tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) to standard chemotherapy before chemoradiation can improve outcomes for people with advanced nasopharyngeal cancer. About 60 adults with non-metastatic, EBV-positive nasopharyngeal carc…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug cocktail aims to beat back aggressive throat cancer
Disease control Not yet recruitingThis Phase 3 trial tests whether adding a targeted drug (Becotatug Vedotin) to standard immunotherapy and chemo-radiation can improve outcomes for people with high-risk nasopharyngeal cancer. About 514 participants will be randomly assigned to receive either the new combo or stan…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New cocktail of drugs aims to stop High-Risk throat cancer in its tracks
Disease control Not yet recruitingThis Phase 3 trial will test whether adding anlotinib (a drug that cuts off tumor blood supply) to standard immunotherapy and chemotherapy with radiation can improve outcomes for 412 people with high-risk nasopharyngeal cancer. Participants will receive either the new combo or st…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could less immunotherapy be just as good for advanced nose cancer?
Disease control Not yet recruitingThis phase 3 trial will test whether a shorter course of the immunotherapy drug tislelizumab, combined with chemotherapy and radiation, works as well as a longer course for people with advanced nasopharyngeal cancer. About 418 participants will be randomly assigned to receive eit…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug duo aims to shrink throat tumors before standard care
Disease control Not yet recruitingThis study tests whether giving two drugs (pembrolizumab and MRG-003) before standard chemoradiation can shrink tumors in people with advanced nasopharyngeal cancer linked to Epstein-Barr virus. About 35 adults with stage III-IVa disease will receive 3 cycles of the drug combo, t…
Phase 2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC